ScreenerHero
EVTEvotec SE
XETRA · DE · Healthcare · Drug Manufacturers - Specialty & Generic · evotec.com
3.354EUR-0.06%Mkt Cap: 648.20M $P/E: —

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biolog…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap648.20M $
Enterprise Value659.30M $
Revenue (TTM)779.66M $
Gross Profit124.15M $
Net Income (TTM)-112.52M $
Revenue/Share4.390 USD
Last Price3.354 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees4.5K
CountryDE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.99
PEG1.43
EV/EBITDA-8.29
EV/Revenue0.85
P/S0.83
P/B0.85
EPS (TTM)-1.11
EPS (Forward)-0.42
52W Range
3.1764% of range7.300
52W High7.300 EUR
52W Low3.176 EUR
Profitability
Gross Margin14.49%
Oper. Margin-62.26%
EBITDA Margin-10.20%
Profit Margin-13.13%
ROE-12.72%
ROA-6.04%
Growth
Revenue Growth-16.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.98M $
CapEx (TTM)89.81M $
FCF Margin-11.29%
FCF Yield-13.58%
Net Debt11.17M $
Net Debt/EBITDA-0.14
Balance Sheet
Debt/Equity0.55
Current Ratio2.33
Quick Ratio2.02
Book Value/Sh3.940 EUR
Cash/Share2.620 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateAug 18, 2000
Analyst Consensus
Rating2.6 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.586 EUR
Upside (mean)+36.7%
Target Range3.500 EUR – 10.00 EUR
€3.500+36.7% to mean€10.00
# Analysts7
Ownership
Shares Out.177.69M
Float135.39M
Insiders9.97%
Institutions61.25%
Technical
SMA 504.107 (-18.3%)
SMA 2005.035 (-33.4%)
Beta1.26
S&P 52W Chg18.16%
Avg Vol (30d)1.06M
Avg Vol (10d)909.84K
Technical Indicators
RSI (14)37.3
MACD-0.1825
MACD Signal-0.2123
MACD Hist.+0.0298
BB Upper3.728 EUR
BB Middle3.484 EUR
BB Lower3.239 EUR
BB Width14.03%
ATR (14)0.1818 EUR
Vol Ratio (20d)0.86x